Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Announces Closing of Offering and Partial Exercise of
Option to Purchase Additional Shares

Mont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced underwritten public offering in the United States, which included shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, in which 5,374,755 shares of its ordinary shares were sold at an offering price of $9.25 (EUR 8.54) per share, before underwriting discounts and commissions. This resulted in total gross proceeds, before deducting underwriting discounts and commissions and other offering expenses payable by Nyxoah, of approximately $50 million (EUR 45.9 million).

In addition, Nyxoah announced today that the underwriters of the Offering have exercised their option to purchase additional shares for 300,000 shares at the public offering price of $9.25 (EUR 8.54) per share, before underwriting discounts and commissions. This exercise will bring the total gross proceeds of the Offering to approximately $52.5 million (EUR 48.5 million) before deducting underwriting discounts and commissions and estimated offering expenses. The closing of the exercise of the option to purchase 300,000 additional shares is expected to occur on June 3, 2024, subject to the satisfaction of customary closing conditions.

Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations.

Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering. Degroof Petercam acted as a co-manager.

The public offering in the United States was made pursuant to an effective shelf registration statement on Form F-3 (File No. 333-268955) that was filed by Nyxoah with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on January 6, 2023. Copies of the final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022; email: prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-Looking Statements
This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements may be identified by words such as “expects,” “potential,” “could,” or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include express or implied statements relating to, among other things, Nyxoah’s current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies; and statements relating to the offering, including the expected closing, the anticipated proceeds from the offering and the use thereof. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Nyxoah’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation, risks relating to market conditions and the Company’s inability, or the inability of the underwriters, to satisfy the conditions for the closing of the offering. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Other risks and uncertainties faced by Nyxoah include those identified under the heading 'Risk Factors' in Nyxoah’s most recent Annual Report on Form 20-F filed with the SEC, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Nyxoah’s views as of the date hereof, and Nyxoah does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contact:
Nyxoah
David DeMartino, Chief Strategy Officer

IR@nyxoah.com

Attachment

  • ENGLISH_Financing Closing and Exercise of Greenshoe Press Release - May 2024


Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional Shares

THỦ THUẬT HAY

Cách mở các tab vừa đóng trên iPhone hoặc iPad

Các trình duyệt trên điện thoại di động hiện đại cho phép bạn mở lại các tab vừa đóng, giống như các trình duyệt trên máy tính để bàn. Trong trình duyệt Safari của Apple dành cho iPhone và iPad, tính năng này ẩn, nhưng

Làm thế nào để iPhone đọc tên người gọi đến khi có cuộc gọi?

Bạn đang bận làm việc gì đó mà không thể cầm iPhone để xem cuộc gọi đến nhưng vẫn muốn biết người gọi là ai, cuộc gọi có quan trọng hay không để trả lời thì mẹo hay dưới đây mà TECHRUM giới thiệu sẽ giúp bạn giải quyết

Smarty Uninstaller: Công cụ hỗ trợ gỡ bỏ phần mềm đang miễn phí bản quyền chính chủ

Chắc hẳn bạn đã không còn xa lạ gì với công cụ hỗ trợ gỡ bỏ phần mềm Your Uninstaller! Tuy nhiên thay vì sử dụng một phiên bản 'bẻ khóa' và tiềm ẩn nhiều mối nguy hại cho thiết bị của mình, TCN xin chia sẻ cùng bạn đọc

Cách lịch sử tìm kiếm trên Google đã lưu trước đó trên mọi thiết bị

Giống như Facebook và Apple, Google đã giới thiệu chính sách bảo mật người dùng mới để tuân thủ luật bảo mật dữ liệu mới của GDPR sẽ có hiệu lực vào ngày 25 tháng 5. Quan trọng hơn, Google đã cải thiện việc kiểm soát

Hướng dẫn sạc và sử dụng Laptop đúng cách

Cách sử dụng Laptop của mỗi người khác nhau và thông thường các bạn đang có những suy nghĩ sai lêch về cách sử dụng. Bài viết dưới đây, dienmayxanh.com sẽ đưa ra một vài gợi ý giúp bạn sử dụng và sạc Laptop một cách

ĐÁNH GIÁ NHANH

So sánh Xiaomi Redmi Note 11, Redmi Note 11 Pro và Redmi Note 11 Pro+

Nếu bạn đang phân vân bản thân nên mua Redmi Note 11, Redmi Note 11 Pro hay bản cao cấp nhất Redmi Note 11 Pro+ thì câu trả lời đang có ở trong bài phân tích này

Đánh giá Surface Pro 6 (2018): Hiệu năng tăng 30%, thiết kế không đổi

Đồng thời cấu hình sử dụng sẽ là vi xử lý thế hệ thứ 8 của Intel (Kabylake-R, không phải CoffeeLake). Chính vì vậy, hiệu năng CPU tăng khoảng 10% đối với hoạt động đơn nhân, và 30-40% đối với hoạt động sử dụng đa nhân.

Đánh giá xe Mercedes GLC 200 2018 về thiết kế vận hành và giá bán

Đánh giá xe Mercedes GLC 200 2018 về thiết kế vận hành và giá bán! Phiên bản GLC 200 vừa chính thức có mặt tại đại lý Vietnam Star TPHCM với giá bán được tiết lộ là 1,684 tỷ đồng, thấp hơn đáng kể so với hai phiên bản